Figure 1: Worldwide Breast Cancer Statistics (by Region), 2018
Figure 2: Impact Analysis of Market Drivers and Market Challenges on the Next-Generation Breast Cancer Diagnostics and Screening Market
Figure 3: Next-Generation Breast Cancer Diagnostics and Screening Market (by Product Type), ($Million), 2020 vs 2030
Figure 4: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2020 vs. 2030
Figure 5: Next-GenerationNext-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2020 vs. 2030
Figure 6: Next-Generation Breast Cancer Diagnostics and Screening Market (by End User), ($Million), 2020 vs. 2030
Figure 7: Next-Generation Breast Cancer Diagnostics and Screening Market Snapshot
Figure 2.1: Next-Generation Breast Cancer Diagnostics and Screening Segmentation
Figure 3.1: Primary Research Methodology
Figure 3.2: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.3: Top-Down Approach (Segment-Wise Analysis)
Figure 5.1: Number of Cases (in Million) by Different Forms of Cancer, 2018
Figure 5.2: Global Incidence of Breast Cancer Cases, As of 2018
Figure 6.1: Share of Key Developments and Strategies, 2017-2020
Figure 6.2: Product Approval Share (by Company), 2017–2020
Figure 6.3: Product Launch and Upgradation Share (by Company), 2017–2020
Figure 6.4: Synergistic Activities Share (by Company), 2017-2020
Figure 6.5: Funding and Expansion Share (by Company), 2017-2020
Figure 6.6: Mergers and Acquisitions Share (by Company), 2017-2020
Figure 6.7: Other Key Development Share (by Company), 2017-2020
Figure 6.8: Market Share Analysis for the Next-Generation Breast Cancer Diagnostics and Screening Market, 2019
Figure 6.9: Growth Share Matrix for Next-Generation Breast Cancer Diagnostics and Screening (by Company), 2019
Figure 7.1: Next-Generation Breast Cancer Diagnostics and Screening Market (by Technology), ($Million), 2019-2030
Figure 7.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (RT-PCR), ($Million), 2019-2030
Figure 7.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (IHC), ($Million), 2019-2030
Figure 7.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (NGS), ($Million), 2019-2030
Figure 7.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (FISH), (($Million)), 2019-2030
Figure 7.6: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Other), 2019-2030 ($ Million)
Figure 8.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Cancer Subtype), ($Million), 2019-2030
Figure 8.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal A), ($Million), 2019-2030
Figure 8.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Luminal B), ($Million), 2019-2030
Figure 8.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Triple-negative/basal-like), ($Million), 2019-2030
Figure 8.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by HER-2 Enriched), ($Million), 2019-2030
Figure 9.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Test Type),($Million), 2019-2030
Figure 9.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (BRCA), ($Million), 2019-2030
Figure 9.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (ER/PR Receptor), ($Million), 2019-2030
Figure 9.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (HER-2), ($Million), 2019-2030
Figure 9.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other), ($Million), 2019-2030
Figure 10.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2020 and 2030
Figure 10.2: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), ($Million), 2019-2030
Figure 10.3: North America Next-Generation Breast Cancer Diagnostic and Screening Market, (($Million)), 2019-2030
Figure 10.4: North America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.5: North America: Market Dynamics
Figure 10.6: U.S. Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.7: Canada Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.8: Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.9: Europe: Market Dynamics
Figure 10.10: Europe Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.11: Germany Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.12: U.K. Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.13: France Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.14: Italy Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.15: Spain Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.16: Rest-of-Europe Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.17: Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 10.18: APAC: Market Dynamics
Figure 10.19: APAC Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Country), ($Million), 2019-2030
Figure 10.20: China Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.21: Japan Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.22: India Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.23: Australia Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.24: Singapore Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.25: RoAPAC Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030
Figure 10.26: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030
Figure 10.27: Latin America: Market Dynamics
Figure 10.28: Latin America Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), ($Million), 2019-2030
Figure 10.29: Brazil Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030,
Figure 10.30: Mexico Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million), 2019-2030,
Figure 10.31: Rest-of-Latin America Next-Generation Breast Cancer Diagnostics and Screening Market, ($Million) 2019-2030
Figure 10.32: RoW Next-Generation Breast Cancer Diagnostic and Screening Market, ($Million), 2019-2030,
Figure 11.1: Next-Generation Breast Cancer Diagnostic and Screening Market (by End User), ($Million), 2019-2030
Figure 11.2: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Hospital-associated labs), 2019-2030 ($ Million)
Figure 11.3: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Cancer Research Institutes), ($Million), 2019-2030
Figure 11.4: Global Next-Generation Breast Cancer Diagnostics and Screening Market (Diagnostic Centers), ($Million), 2019-2030
Figure 11.5: Global Next-Generation Breast Cancer Diagnostics and Screening Market (by Other End Users), 2019-2030
Figure 12.1: Total Number of Companies Profiled
Figure 12.2: Abbott Laboratories: Portfolio
Figure 12.3: Abbott Laboratories: Overall Financials, 2017-2019
Figure 12.4: Abbott Laboratories: Revenue (by Segment), 2017-2019
Figure 12.5: Abbott Laboratories: Revenue Split for Diagnostics, 2017-2019
Figure 12.6: Abbott Laboratories: Revenue (by Region), 2017-2019
Figure 12.7: Abbott Laboratories: R&D Expenditure, 2017-2019
Figure 12.8: Abbott Laboratories: SWOT Analysis
Figure 12.9: Agendia: Product Portfolio
Figure 12.10: Agendia: SWOT Analysis
Figure 12.11: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 12.12: Agilent Technologies, Inc.: Overall Financials, 2017-2019
Figure 12.13: Agilent Technologies, Inc.: Revenue (by Segment), 2017-2019
Figure 12.14: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
Figure 12.15: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
Figure 12.16: Agilent Technologies, Inc.: SWOT Analysis
Figure 12.17: Ambry Genetics: Product portfolio
Figure 12.18: Ambry Genetics: SWOT Analysis
Figure 12.19: Biocept, Inc.: Portfolio
Figure 12.20: Biocept, Inc.: Overall Financials, 2017-2019
Figure 12.21: Biocept, Inc.: Sales (by Segment), 2017-2019
Figure 12.22: Biocept, Inc.: R&D Expenditure, 2017-2019
Figure 12.23: Biocept, Inc.: SWOT Analysis
Figure 12.24: Biotheranostics, Inc.: Product Portfolio
Figure 12.25: Biotheranostics, Inc.: SWOT Analysis
Figure 12.26: CENTOGENE N.V.: Overall Product Portfolio
Figure 12.27: CENTOGENE N.V.: Overall Financials, 2017-2019
Figure 12.28: CENTOGENE N.V.: Sales (by Segment), 2016-2018
Figure 12.29: CENTOGENE N.V.: Sales (by Region), 2017-2019
Figure 12.30: CENTOGENE N.V.: R&D Expenditure, 2017-2019
Figure 12.31: CENTOGENE N.V.: SWOT Analysis
Figure 12.32: Danaher Corporation: Product Portfolio
Figure 12.33: Danaher Corporation: Overall Financials, 2017-2019
Figure 12.34: Danaher Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.35: Danaher Corporation: Revenue (by Region), 2017-2019
Figure 12.36: Danaher Corporation: R&D Expenditure, 2016-2018
Figure 12.37: Danaher Corporation: SWOT Analysis
Figure 12.38: Exact Science Corporation: Product Portfolio
Figure 12.39: Exact Sciences Corporation: Overall Financials, 2017-2019
Figure 12.40: Exact Sciences Corporation: Revenue (by Business Segment), 2017-2019
Figure 12.41: Exact Sciences Corporation: Revenue (by Region), 2017-2019
Figure 12.42: Exact Sciences Corporation: R&D Expenditure, 2017-2019
Figure 12.43: Exact Sciences Corporation: SWOT Analysis
Figure 12.44: F. Hoffmann-La Roche Ltd.: Portfolio
Figure 12.45: F. Hoffmann-La Roche Ltd.: Overall Financials, 2017-2019
Figure 12.46: F. Hoffmann-La Roche Ltd.: Sales (by Segment), 2017-2019
Figure 12.47: F. Hoffmann-La Roche Ltd: Sales (by Region), 2017-2019
Figure 12.48: F. Hoffmann-La Roche Ltd.: R&D Expenditure, 2017-2019
Figure 12.49: F. Hoffmann-La Roche Ltd.: SWOT Analysis
Figure 12.50: Fulgent Genetics: Product Portfolio
Figure 12.51: Fulgent Genetics: Overall Financials, 2017-2019
Figure 12.52: Fulgent Genetics: Revenue (by Business Segment), 2018-2019
Figure 12.53: Fulgent Genetics: Revenue (by Region), 2017-2019
Figure 12.54: Fulgent Genetics: R&D Expenditure, 2017-2019
Figure 12.55: Fulgent Genetics: SWOT Analysis
Figure 12.56: Illumina, Inc.: Portfolio
Figure 12.57: Illumina, Inc.: Overall Financials, 2017-2019
Figure 12.58: Illumina, Inc.: Revenue (by Segment), 2017-2019
Figure 12.59: Illumina, Inc.: Revenue (by Region), 2017-2019
Figure 12.60: Illumina, Inc.: R&D Expenditure, 2017-2019
Figure 12.61: Illumina, Inc.: SWOT Analysis
Figure 12.62: Invitae Corporation: Overall Product Portfolio
Figure 12.63: Invitae Corporation: Overall Financials, 2017-2019
Figure 12.64: Invitae Corporation: Revenue (by Segment), 2017-2019
Figure 12.65: Invitae Corporation: Revenue (by Geography), 2017-2019
Figure 12.66: Invitae Corporation: R&D Expenditure, 2017-2019
Figure 12.67: Invitae Corporation: SWOT Analysis
Figure 12.68: Lucene Diagnostics Pte Ltd: Product Portfolio
Figure 12.69: Lucene Diagnostic Pte Ltd: SWOT Analysis
Figure 12.70: Myriad Genetics, Inc.: Overall Product Portfolio
Figure 12.71: Myriad Genetics, Inc.: Overall Financials, 2017-2019
Figure 12.72: Myriad Genetics, Inc.: Revenue (by Business Segment), 2017-2019
Figure 12.73: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
Figure 12.74: Myriad Genetics, Inc.: SWOT Analysis